Updated:
FemHealth Ventures
FemHealth Ventures invests in women’s health innovations. The firm aims to transform women’s health by investing in groundbreaking health solutions while...
FemHealth Ventures
FemHealth Ventures invests in women’s health innovations. The firm aims to transform women’s health by investing in groundbreaking health solutions while achieving exceptional financial returns. As part of its investment approach, it created a three-category framework defining women’s health as conditions appearing only in women, mostly in women, and differently in women.
General information
Firm type
Venture Capital
Year founded
2020
Location
Region
North America
Country
United States
City
New York
Corporate office
New York, NY, United States
Principals
Maneesha Ghiya
Managing Partner
Sara Crown Star
Venture Partner
Stephanie Wang
Investor
Sector focus
Frequently asked questions
What is the FemHealth Framework, and why does it matter for deal sourcing?
Published by the firm in 2019, the FemHealth Framework sorts women's health conditions into three buckets: those appearing only in women, mostly in women, or differently in women. It functions as a proprietary sourcing screen, ensuring that portfolio companies address diseases where XX-chromosomal biology alters the clinical presentation or market need. The framework has been broadly adopted across the women's health investment ecosystem.
Which women's health categories does the firm explicitly invest in?
The firm invests across conditions that are only in women — such as endometriosis and cervical cancer — mostly in women, including breast cancer and lupus, and differently in women, like heart disease and diabetes. Its portfolio reflects this, holding companies in medical devices, therapeutics, diagnostics, and biobanking, all filtered through this lens.
Who leads investment decisions at FemHealth Ventures?
Managing Partner Maneesha Ghiya leads the firm, supported by Venture Partner Sara Crown Star and Investor Stephanie Wang. Ghiya and Crown Star share a 30-year professional relationship. The firm also relies on an advisory board that includes biotech CEOs, surgeons, and faculty from Harvard Business School and Wharton.
What is the firm's known posture on co-investments or syndication alongside other VCs?
The firm has not publicly detailed its syndication or co-investment practices. Published materials emphasize its proprietary sourcing lens rather than preferred deal structures, leaving its approach to leading versus following rounds unspecified.
What is the scale of the firm's deployment to date, and has it closed a formal fund?
No AUM or total deployment figure is publicly disclosed by the firm. It lists a portfolio of 21 named companies on its website, implying meaningful capital at work, but it has issued no press release confirming a fund size or close date.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on venture capital firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: